Company news
Denali Therapeutics Inc. news in 2022
Denali Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
December 4, 2022
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 2, 2022
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV: PGRN) and Progression to Enrolling Participants with FTD-GRN
October 31, 2022
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 23, 2022
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
October 18, 2022
Denali Therapeutics Announces Proposed Offering of Common Stock
October 17, 2022
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
October 2, 2022
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV: IDS) in MPS II (Hunter Syndrome) at SSIEM 2022
August 30, 2022
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 7, 2022
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
May 30, 2022
Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 4, 2022
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
May 1, 2022
Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors
March 14, 2022
Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV: PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)
March 8, 2022
Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
February 27, 2022
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
February 27, 2022
Denali Therapeutics Announces Continued Progress in DNL310 (ETV: IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial
February 9, 2022
Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors
February 6, 2022
Denali Therapeutics Announces Presentations on DNL310 (ETV: IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™
January 31, 2022
Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application
January 12, 2022
Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022
January 9, 2022